The earnings call indicated a strong performance in the launch and growth of Attruby, with significant advancements in the pipeline and financial growth. However, increased operating costs and competitive pressures were noted as challenges.

Company Guidance

During BridgeBio Pharma's Second Quarter 2025 Earnings Call, the company highlighted several key metrics reflecting the strong performance and growth potential of their product, Attruby. They reported a significant increase in unique patient prescriptions, reaching 3,751, and noted 1,074 unique prescribers. Weekly script growth exceeded 30%, surpassing internal projections. The company's revenue for Q2 showed a remarkable 100% growth, with global sales reaching $78 million and U.S. net sales at $71.5 million. Attruby's success in the market is driven by its clinical efficacy, highlighted by a 59% hazard reduction in time to first event in a specific patient subpopulation, and strong prescriber and patient adoption. The company continues to focus on expanding their late-stage pipeline with three key Phase III trials, positioning themselves for further growth in the coming months. Additionally, they have maintained a strong cash position of $756.9 million, reinforcing their financial flexibility to pursue strategic initiatives.

Strong Launch of Attruby

Attruby achieved $71.5 million in U.S. net sales, showing 100% growth from Q1. The total unique patient prescriptions reached 3,751 with 1,074 unique prescribers.

Pipeline Progress

BridgeBio is preparing for three Phase III readouts in ADH1, LGMD2I, and achondroplasia, each representing significant market opportunities.

Financial Growth

Total Q2 revenues were $110.6 million, a significant increase from $2.2 million in the previous year, primarily driven by Attruby's sales.

Positive Clinical Data for Attruby

Attruby showed a 59% hazard reduction in time to first event CVH or ACM in the variant population with a p-value of 0.011, and a 43% reduction in risk of CVH associated with cardiac arrhythmia.

Strong Cash Position

BridgeBio ended Q2 with $756.9 million in cash, cash equivalents, and marketable securities, providing financial flexibility.

BridgeBio Pharma (BBIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BBIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.83 / -	-0.86	―	―	―
Aug 05, 2025	2025 (Q2)	-0.79 / -0.95	-0.39	-143.59% (-0.56)	―
Apr 29, 2025	2025 (Q1)	-0.92 / -0.88	-0.2	-340.00% (-0.68)	―
Feb 20, 2025	2024 (Q4)	-1.12 / -1.40	-0.96	-45.83% (-0.44)	―	―
Nov 12, 2024	2024 (Q3)	-1.00 / -0.86	-1.08	20.37% (+0.22)	―	―
Aug 01, 2024	2024 (Q2)	-1.00 / -0.39	-0.98	60.20% (+0.59)	―	―
May 02, 2024	2024 (Q1)	-0.74 / -0.20	-0.92	78.26% (+0.72)	―	―
Feb 22, 2024	2023 (Q4)	-0.87 / -0.96	-0.92	-4.35% (-0.04)	―	―
Nov 02, 2023	2023 (Q3)	-0.79 / -1.08	-0.93	-16.13% (-0.15)	―	―
Aug 03, 2023	2023 (Q2)	-0.80 / -0.98	-0.07	-1300.00% (-0.91)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BBIO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$49.21	$44.81	-8.94%
Apr 29, 2025	$36.42	$38.36	+5.33%
Feb 20, 2025	$36.29	$36.80	+1.41%
Nov 12, 2024	$26.12	$24.62	-5.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bridgebio Pharma (BBIO) report earnings?

Bridgebio Pharma (BBIO) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Bridgebio Pharma (BBIO) earnings time?

Bridgebio Pharma (BBIO) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BBIO EPS forecast?

BBIO EPS forecast for the fiscal quarter 2025 (Q3) is -0.84.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing